RHK.DU RHOEN-KLINIKUM
- Market cap
- -
- P/E
- 22.7x
- P/B
- 0.72x
- ROE
- 3.3%
- Dividend yield
- 0.83%
- Fundamental score
- 2.0/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is RHK.DU undervalued?
Graham numberThe Graham number of RHOEN-KLINIKUM cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RHOEN-KLINIKUM fundamental analysis
10 of 22 checks passedROE 0/2
Low return on equity (3.3%), below 10%.
ROA 0/1
Return on assets (2.4%) is below the industry median (3.8%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-20.5%) is not above the 5-year average (88.4% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-20.5%) is below the industry median (7.9%).
Revenue Growth 1/2
Revenue grew 5.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
EBIT is 21.8x against interest expense, well covered.
PE vs Market 0/1
PE (22.7x) is above the market median (18.2x).
PE vs Industry 0/1
PE (22.7x) is above the industry median (18.3x).
PBV 1/1
Price to book (0.7x) is below the industry median (2.0x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 16.3, limit 22.5).
PEG 1/1
PEG on 5-year earnings growth is 0.26, growth is cheap.
Dividend Yield 0/2
Dividend yield (0.7%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 19.4%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
RHOEN-KLINIKUM stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
RHOEN-KLINIKUM financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
RHOEN-KLINIKUM annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.18B | 1.21B | 1.23B | 1.30B | 1.36B | 1.40B | 1.45B | 1.46B | 1.60B | 1.70B | 1.73B |
| Gross Profit | 847M | 864M | 860M | 896M | 938M | 198M | 199M | 149M | 172M | 193M | 571M |
| Operating Income | 107M | 50.1M | 65.3M | 57.0M | -804K | 29.7M | 36.3M | 29.6M | 37.5M | 29.0M | 56.6M |
| EBITDA | - | 97.0M | 126M | 126M | 81.1M | 101M | 107M | 117M | 122M | 113M | 121M |
| Net Income | 56.4M | 35.2M | 49.0M | 43.3M | 1.45M | 28.3M | 25.1M | 38.7M | 43.4M | 34.5M | 43.5M |
| EPS | - | 0.53 | 0.73 | 0.65 | 0.02 | 0.42 | 0.38 | 0.58 | 0.65 | 0.51 | 0.65 |
| Balance Sheet | |||||||||||
| Total Assets | 1.46B | 1.47B | 1.59B | 1.63B | 1.63B | 1.67B | 1.70B | 1.77B | 1.86B | 1.82B | 1.83B |
| Total Liabilities | 343M | 346M | 430M | 446M | 439M | 441M | 454M | 490M | 531M | 468M | 467M |
| Shareholders' Equity | 1.09B | 1.10B | 1.14B | 1.16B | 1.17B | 1.20B | 1.22B | 1.25B | 1.30B | 1.32B | 1.33B |
| Cash & Short-term Investments | 80.8M | 122M | 132M | 128M | 91.0M | 126M | 77.3M | 206M | 280M | 170M | 133M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 109M | 80.3M | 49.5M | 47.3M | 113M | 97.5M | 60.3M | 109M | 128M | 57.2M | - |
| Capital Expenditure | 114M | 116M | 163M | 115M | 97.0M | 77.8M | 58.2M | 62.8M | 70.4M | 99.1M | 0.00 |
| Free Cash Flow | - | -35.5M | -114M | -67.2M | 16.3M | 19.7M | 2.10M | 46.2M | 57.2M | -41.9M | - |
| Ratios | |||||||||||
| ROE | 5.2% | 3.2% | 4.3% | 3.7% | 0.1% | 2.4% | 2.1% | 3.1% | 3.3% | 2.6% | 3.3% |
| ROA | 3.9% | 2.4% | 3.1% | 2.7% | 0.1% | 1.7% | 1.5% | 2.2% | 2.3% | 1.9% | 2.4% |
| Net Profit Margin | 4.8% | 2.9% | 4.0% | 3.3% | 0.1% | 2.0% | 1.7% | 2.6% | 2.7% | 2.0% | 2.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
RHOEN-KLINIKUM dividends
- Dividend yield
- 0.83%
- Forward dividend
- -
- Payout ratio
- 19.4%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 6.70M | 0.10 | 19.4% |
| 2024 | - | - | - |
| 2023 | EUR 10.0M | 0.15 | 25.8% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | EUR 19.4M | 0.29 | 44.8% |
| 2018 | EUR 14.7M | 0.22 | 30.0% |
| 2017 | EUR 23.4M | 0.35 | 66.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jul 13, 2007.
Who owns RHOEN-KLINIKUM
Ownership data of RHOEN-KLINIKUM is not available yet.
RHOEN-KLINIKUM company profile
- Company name
- RHOEN-KLINIKUM
- Ticker
- RHK.DU
- Exchange
- Dusseldorf Exchange
- Sector
- Other
- Industry
- Metals & Mining
- Fiscal year end
- December
- Address
- Website
- -
About RHOEN-KLINIKUM
There is no Profile data available for RHK.DU.